Shimadzu Scientific Instruments, Cure Pharmaceutical Corp and CK Sciences Form a Strategic Alliance for R&D of Pharmaceutical Cannabis Products
Columbia, MD (October 25, 2017) — Shimadzu Scientific Instruments, the leading provider of cannabis testing instruments, announces it has signed a Memorandum of Understanding (MOU) with Cure Pharmaceutical Corp and CK Sciences. This collaborative agreement will focus on researching and developing safer pharmaceutical cannabis-based products and moving these products through clinical trials using FDA guidelines.
Shimadzu, Cure Pharmaceutical Corp and CK Sciences will be researching and profiling the synergistic effects of the cannabinoids and terpenes often referred to as the “Entourage Effect”. The organizations will be using Shimadzu’s Cannabis Analyzer for Potency, a high performance liquid chromatograph (HPLC) designed specifically for quantitative determination of cannabinoid content, as well as a headspace Gas Chromatograph Mass Spectrometer (GCMS) for terpene profiling. Shimadzu will train laboratory personnel and be a single-source contact for technical support. Cure/CK Sciences will utilize these instruments to demonstrate their performance capabilities and generate data for the purpose of validating cannabis as a viable pharmaceutical treatment.
"When we dove head first into pharmaceutical cannabis research, we knew we needed to start outfitting our lab to be ready for what was to come,” said Tracy Ryan, CEO & Founder, CK Sciences. “When we met with Shimadzu, and we saw their passion for our mission, we knew we were in incredible hands! When analyzing cannabis everything has to be so precise. With Shimadzu's platforms and team of brilliant scientists supporting our efforts, we have already set ourselves up for success.”
“The emerging pharmaceutical cannabis market requires dedicated, thoughtful leaders eager to showcase the pharmaceutical benefits of cannabis on a scientific level,” said Bob Clifford, Ph.D., General Manager of Marketing, Shimadzu Scientific Instruments. “The Cure/CK Sciences group has continuously demonstrated such a leadership commitment, and we’re excited about the opportunities this agreement provides.”